Dextromethorphan (DXM) is a cough suppressant approved by the Food and Drug
Administration (FDA) that is found in many over-the-counter cough and cold
remedies.1 It is generally safe when taken at
recommended doses. When taken in large amounts, though, DXM can produce
hallucinations and a "high" similar to psychotropic drugs, such as phencyclidine
(PCP). Dangerous side effects may include blurred vision, loss of physical
coordination, abdominal pain, and rapid heartbeat. Side effects may be worsened
if the ingested product also contains other pharmaceutical ingredients—such as
acetaminophen, pseudoephedrine, antihistamines, or expectorants, which are
commonly found in cough and cold medicines—or alcohol.2
In recent years DXM has become available, primarily over the Internet, in
bulk powdered form, and concern has grown over the nonmedical use of DXM by
teenagers. In May 2005, the FDA issued a warning about the dangers of DXM abuse
involving over-the-counter products and DXM obtained from illicit sources.3
The Drug Abuse Warning Network (DAWN) collects data from a national sample of
short-term, general, non-Federal hospitals4 and publishes estimates of emergency
department (ED) visits involving illicit drugs and nonmedical use of
pharmaceuticals. This issue of The DAWN Report examines the
characteristics of ED visits that involve DXM and products containing DXM.
Included are findings on the age of ED patients who used DXM and the reason for
their visit to the ED. Also provided are the rates of DXM-related ED visits per
100,000 population for different age groups and the frequency with which DXM
products are found in combination with alcohol. The ED visits considered here
exclude the small number of patients who go to the ED to obtain admission to the
hospital's detoxification or substance abuse treatment unit.
Overview
During 2004, there were about 106 million ED visits to short-term,
general, non-Federal hospitals in the United States.5 Of those, DAWN estimates that just over
2.5 million were drug related, with just under a half million involving
nonmedical use of pharmaceuticals. Nearly 17,000, or just under 1 percent,
of all drug-related ED visits in 2004 involved DXM or products containing
DXM.
Reasons for ED visits
Nonmedical use of DXM products accounted for 5,962 (35%) of the estimated
16,858 DXM-related ED visits in 2004, and about half (51%) of these nonmedical
visits involved patients aged 12 to 20 (Table 1).6 The rate of ED visits resulting from
nonmedical use of DXM products was 8.0 visits per 100,000 population for those
aged 12 to 20, while the rate for other age groups was 2.5 or less (Table 1
and Figure 1).
Medical use of DXM included ED visits attributed to adverse reactions that
occured when DXM products were used as prescribed (or according to directions
for over-the-counter products). About 31 percent of all DXM-related ED
visits in 2004 were a result of adverse reactions. Children aged 0 to 11 are the
most likely to experience adverse reactions to DXM. Their rate of ED visits was
higher than that for any other age group (3.9 per 100,000 population), and they
constitute 36 percent of all ED visits involving adverse reactions to
DXM.
About 16 percent of DXM-related ED visits involve accidental ingestion.
As with adverse reactions, children aged 0 to 11 are also the most likely to
accidentally ingest DXM or DXM-containing products. The rate of ED visits for
accidental ingestion of DXM is 5.2 visits per 100,000 population, and over
95 percent of ED visits for accidental ingestion of DXM involve children in
this age range.
Suicide attempts involving DXM products accounted for 17 percent of
DXM-related ED visits. Patients aged 12 to 20 are more likely than patients in
other age groups to use DXM products in a suicide attempt. This group has a rate
of 4.3 DXM-related ED visits per 100,000 population, compared with rates of 0.0
for those aged 0 to 11 and less than 1.0 for those aged 21 or
older.
Alcohol involvement
Alcohol was involved in about 13 percent of ED visits resulting from
nonmedical use of DXM products for those aged 12 to 17 and in 41 percent of
such visits for those aged 18 to 20 (Figure 2). Patients aged 35 to 54 had
the highest involvement of alcohol (61%). For the youngest (aged 0 to 11) and
oldest (aged 55 or older) patients, alcohol involvement was lower (0% and 2%,
respectively).
Alcohol is also an ingredient in some cough medications. Some common products
(e.g., NyQuil®) contain a mixture of DXM and up to 10 percent
alcohol. In these cases, alcohol may play a role in the ED visit without being
specifically documented in the ED medical record. Therefore, these findings may
understate the involvement of alcohol and its contribution to the side effects
leading to ED visits.